Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding the use of these agents. One ongoing challenge is the prevention and management of CAR-T-related toxicities, including immune effector cell-associated hematotoxicity (ICAHT), as well as how to improve affordability and access to these agents.
In this podcast, you will hear from Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, who discusses the importance of lymphodepletion in CAR-T therapy, Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York, NY, who updates us on ICAHT, and Gérard de Pouvourville, PhD, ESSEC Business School, Cergy, France, who shares his thoughts on the cost effectiveness of these agents.
CAR T-cell therapy & multiple myeloma: past, present & future
Harnessing the tumor microenvironment in lymphoma therapy
Induction therapy in myeloma: an ever-changing paradigm
Precision epigenetic therapy for B-cell lymphoma
Acute leukemia: pushing boundaries in disease management
iwAL 2019: looking to the future of acute leukemia therapy
CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma
MRD testing in multiple myeloma: new technology with promising clinical applications
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
Patient discussion at EHA 2018: CAR T-cells and MRD in CLL
CLL therapies today: novel agents, combinations & the future of the field
CAR T-cell therapy: where are we now and what’s in store for the future?
Focus on MRD: current landscape and future questions in hemonc
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Acute leukemias: is MRD already a surrogate for survival?
Revolutionary immunotherapies for lymphoma
Latest advances and current challenges in immunotherapies for lymphoma
The circle of CLL: from gene discovery to targeted treatment
Debate on the use of MRD for multiple myeloma management
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive